Literature DB >> 1911147

Somatic growth in corticosteroid-treated rats with passive Heymann nephritis--effects of recombinant human growth hormone on growth impairment.

H Kawaguchi1, M Hattori, M Kohno, K Ito, N Hizuka, K Takano.   

Abstract

We evaluated the efficacy of recombinant human growth hormone (r-hGH) on corticosteroid (CS)-induced growth-impaired rats with proteinuria (passive Heymann nephritis. R-hGH (2 IU twice daily) improved growth in rats treated with 20 mg/kg per day of prednisolone succinate in our 4-week study. Although plasma hGH was significantly increased in rats treated with r-HGH, plasma insulin-like growth factor-1 levels were not different between treated and untreated rats. The food utilization rate was significantly improved by r-hGH. R-hGH did not affect proteinuria, renal function, or calcium and phosphate metabolism. Our results suggest that r-hGH may be effective in improving growth impairment due to CS administration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911147     DOI: 10.1007/bf00856650

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  24 in total

1.  Effects of prolonged cortisone therapy on the statural growth, skeletal maturation and metabolic status of children.

Authors:  F M BLODGETT; L BURGIN; D IEZZONI; D GRIBETZ; N B TALBOT
Journal:  N Engl J Med       Date:  1956-04-05       Impact factor: 91.245

2.  Long-term dwarfing effects of corticosteroid treatment for childhood nephrosis.

Authors:  C N Lam; G C Arneil
Journal:  Arch Dis Child       Date:  1968-10       Impact factor: 3.791

3.  A longitudinal study of the growth of the black-hooded rat: methods of measurement and rates of growth for skull, limbs, pelvis, nose-rump and tail lengths.

Authors:  P C Hughes; J M Tanner
Journal:  J Anat       Date:  1970-03       Impact factor: 2.610

4.  Improvement of growth and food utilization by human recombinant growth hormone in uremia.

Authors:  O Mehls; E Ritz; E B Hunziker; P Eggli; U Heinrich; J Zapf
Journal:  Kidney Int       Date:  1988-01       Impact factor: 10.612

5.  Corticosteroid-induced dwarfism in Still's disease treated with human growth hormone. Clinical and metabolic effects including hydroxyproline excretion in two cases.

Authors:  D J Ward; M Hartog; B M Ansell
Journal:  Ann Rheum Dis       Date:  1966-09       Impact factor: 19.103

6.  Somatomedin inhibitor in uremia.

Authors:  L S Phillips; A C Fusco; T G Unterman; F del Greco
Journal:  J Clin Endocrinol Metab       Date:  1984-10       Impact factor: 5.958

7.  Plasma growth hormone concentration in corticosteroid-treated children.

Authors:  H G Morris; J R Jorgensen; S A Jenkins
Journal:  J Clin Invest       Date:  1968-03       Impact factor: 14.808

8.  Growth hormone stimulates longitudinal bone growth directly.

Authors:  O G Isaksson; J O Jansson; I A Gause
Journal:  Science       Date:  1982-06-11       Impact factor: 47.728

9.  Effect of reimmunization with Fx1A late in the course of Heymann nephritis.

Authors:  B Noble; J B Van Liew; J R Brentjens; G A Andres
Journal:  Lab Invest       Date:  1982-11       Impact factor: 5.662

10.  Somatic growth and renal function in pediatric renal transplantation with alternate-day steroid immunosuppression using cyclosporine (CsA) in Japan.

Authors:  H Kawaguchi; Y Komatsu; M Hattori; M Nagata; K Ito; K Takahashi; S Teraoka; H Toma; K Ota
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.